DIXI medical is pleased to share that, as of October 1st, 2025, we have reestablished our direct sales operations in the United States. This transition marks the end of our distribution agreement with NeuroPace and signals a new chapter in our commercial strategy.

By managing our U.S. sales directly, we’re enhancing our ability to deliver cutting-edge technologies and maintain competitive pricing tailored to the needs of our American customers. This strategic shift strengthens our margins and reinforces our long-term commitment to delivering exceptional value and service.

“Our renewed presence in the U.S. market gives us the flexibility to respond swiftly to clinical needs and bring forward innovations in epilepsy care,” said Frédéric Koehn, Chairman & CEO of DIXI medical Holding. “We’re confident in our team’s ability to ensure a seamless transition and are actively investing in talent to support our growth.”

We’re also excited to welcome Krisahn Gren as Vice President of Sales for the U.S.,bringing extensive industry expertise and a deep commitment to epilepsy care. Krisahn will lead our efforts to build a robust sales team focused on clinical support and nationwide coverage.

“This is a pivotal moment for DIXI medical in the U.S.,” said Krisahn Gren. “We’re building a dynamic team of professionals who are passionate about transforming epilepsy care. We invite talented professionals who share our passion to join our team.”

In parallel with our commercial expansion, we continue to invest in education. Our SEEG training program, originally launched in the U.S. in 2022, has now expanded globally, supporting clinicians with hands-on learning and expert-led instruction. In February 2026, we will host the very first Pediatric SEEG course in South Carolina. This first-of-its-kind event is designed to address the unique complexities of SEEG in children, offering a rare and focused learning opportunity for clinicians dedicated to advancing pediatric epilepsy care.

This renewed focus underscores our leadership in precision epilepsy care and our ongoing dedication to innovation, education, and team growth in the U.S.market.

‍